Ipamorelin vs Tesamorelin
A selective GH secretagogue that mimics ghrelin at GHS-R. An FDA-approved GHRH analog that selectively trims visceral fat. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Ipamorelin | Tesamorelin | |
|---|---|---|
| Also known as | — | Egrifta |
| Type | Analog | Analog |
| Evidence | Preclinical | Clinical |
| Family | Growth & repair | Growth & repair |
| Class | Synthetic pentapeptide GH secretagogue (GHRP) | Stabilized GHRH(1-44) analog |
| Receptor | Growth hormone secretagogue receptor (GHS-R1a) | GHRH receptor (GHRHR), a class B GPCR |
| Molecular weight | ~711.9 Da | ≈5,136 Da |
| Half-life | ||
| Based on | Ghrelin | Growth-hormone-releasing hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Ipamorelin and Tesamorelin?
- Ipamorelin is an engineered analog based on Ghrelin; Tesamorelin is an engineered analog based on Growth-hormone-releasing hormone. Ipamorelin signals at Growth hormone secretagogue receptor (GHS-R1a); Tesamorelin signals at GHRH receptor (GHRHR), a class B GPCR.
- How do the half-lives of Ipamorelin and Tesamorelin compare?
- The reported circulating half-life of Ipamorelin is ~2 h; Tesamorelin is ~26-38 min (subcutaneous). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tesamorelin vs Ipamorelin. Or open the interactive comparison tool to add more molecules.